Continuous Glucose Monitoring Systems – A Growing Market

Diabetes can be called a global pandemic – there are 415 million people affected by it worldwide right now and the number is expected to grow to 642 million in 2040. In 2015 one out of 11 adults had diabetes, in 2040 the number will be one out of 10. High blood sugar is the third highest risk factor for premature mortality, after high blood pressure and tobacco use. In 2015 about 5 million people died from diabetes.

As diabetics are producing too little insulin or none at all (depending on the type of diabetes), the most important aspect when talking about diabetes is the constant availability of high quality insulin. The big names in this market are Sanofi (NYSE: SNY), Eli Lilly and Company (NYSE: LLY), Merck & Co Inc. (NYSE: MRK) and of course the diabetes giant Novo Nordisk (NYSE: NVO). But aside from the ability to administer insulin the diabetic has to be able to measure his or her blood sugar and in the last decade there have been some very interesting developments in this field. In this article, we talk about the future of blood sugar measurement and take a closer look at that market as well as a possible catalyst for continuous glucose monitoring systems…

Continue reading (on Seeking Alpha)